Finally, the interaction of MYCN with the transcription factor HAND2 (heart and neural crest derivatives-expressed protein 2), that permits MYCN chromosome accessibility and enhancer binding in neuroblastoma, was abolished by the Aurora-A inhibitor alisertib, disrupting tumour growth [200]. The gene discussed is HAND2; the disease is neoplasm.